The Pzp Knockout MH-S Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the MH-S mouse alveolar macrophage cell line. This product features targeted disruption of the Pzp gene, which encodes a broad-spectrum protease inhibitor, creating a stable loss-of-function model for dissecting protease-dependent regulatory networks in pulmonary innate immunity. The CRISPR/Cas9 system was utilized to introduce gene disruptions, resulting in a cell line with ablated Pzp function suitable for diverse experimental applications in inflammation, protease biology, and signal transduction. By eliminating Pzp expression, this cell line enables precise examination of Notch-mediated immunomodulation and matrix metalloproteinase regulation without confounding protease inhibition.
The MH-S cell line, originally derived from BALB/c mouse alveolar macrophages, faithfully recapitulates key functional attributes of primary macrophages, including phagocytic uptake, cytokine secretion, and responsiveness to microbial stimuli such as lipopolysaccharide (LPS). As a well-characterized in vitro model, MH-S cells are widely used to investigate pulmonary innate immune defense, acute lung injury, pulmonary fibrosis, and chronic inflammatory disorders. The knockout of Pzp within this cellular context provides a pertinent system for exploring how alveolar macrophage-derived protease inhibitors modulate tissue homeostasis and inflammatory pathology. This model retains the native macrophage phenotype while specifically removing a critical negative regulator of extracellular proteolysis.
Pzp is an acute-phase protein and broad-spectrum protease inhibitor that functions downstream of Notch signaling. In macrophages, activation of Notch1 or Notch2 receptors triggers RBP-J-dependent transcription of Pzp, which subsequently modulates extracellular matrix remodeling by inhibiting matrix metalloproteinases, particularly MMP-9. Pzp expression is also induced by pro-inflammatory cytokines such as IL-6 and TNF-alpha, and by LPS through NF-??B and JAK-STAT pathways. By dampening MMP activity, Pzp indirectly restricts the release of pro-inflammatory mediators and preserves matrix integrity. Thus, Pzp operates at the intersection of Notch, acute-phase, and inflammatory signaling cascades, acting as a molecular brake on excessive inflammation and matrix degradation.
In alveolar macrophages, Pzp-mediated protease inhibition is crucial for containing destructive proteolysis during pulmonary inflammation. Disruption of Pzp in the MH-S background eliminates this regulatory layer, offering a powerful tool to study how unchecked MMP activity contributes to alveolar damage, fibrotic remodeling, and inflammatory diseases such as chronic obstructive pulmonary disease and acute respiratory distress syndrome. The Pzp Knockout MH-S Cell Line allows researchers to delineate the contributions of macrophage-derived protease inhibitors to lung pathology and to investigate the crosstalk between Notch signaling, protease networks, and cytokine circuits in a disease-relevant cellular system. This model provides a window into Notch-dependent immunomodulation and the molecular determinants of macrophage heterogeneity in the inflamed lung.
This knockout cell line is ideal for a broad range of functional assays, including western blotting, RT-qPCR, protease activity measurements, phagocytosis and migration assays, cytokine secretion profiling, immunofluorescence staining, and flow cytometry. Researchers can employ the Pzp Knockout MH-S Cell Line to probe macrophage-mediated inflammation, Notch-driven innate immune responses, protease inhibition mechanisms, and acute-phase reaction pathways. It is particularly valuable for interrogating the signaling relationships among Pzp, Notch receptors (Notch1, Notch2), the transcription factor RBP-J, MMP-9, and pro-inflammatory cytokines. For further details or to discuss custom applications, please contact Ascent Research.
